Published in:
01-11-2019 | ANCA-Associated Vasculitis | Correction
Correction to: Regional prescription surveillance of phosphate binders in the western Saitama area: the substantial role of ferric citrate hydrate in improving serum phosphorus levels and erythropoiesis
Published in: Clinical and Experimental Nephrology | Issue 11/2019
Login to get accessExcerpt
In the Original publication, Under the Table 1, the number of participants in the April has been incorrectly published as 1373. The corrected table is given below:
Table 1 Patient characteristics
|
Characteristics
|
April
|
September
|
p value
|
|---|---|---|---|
|
Participants
|
1374
|
||
|
Sex (male %)
|
63
|
||
|
Age
|
68 [60–76]
|
||
|
Dialysis vintage
|
6 [3–10]
|
||
|
Etiology of renal failure (%)
|
|||
|
Diabetic nephropathy
|
38
|
||
|
Chronic glomerular nephritis
|
18
|
||
|
Nephrosclerosis
|
14
|
||
|
Polycystic kidney disease
|
5
|
||
|
ANCA associated vasculitis
|
0.8
|
||
|
Others
|
24
|
||
|
PTX history (%)
|
1
|
||
|
BMI (kg/m2)
|
21.3 [19.2–23.8]
|
21.2 [19.1–23.9]
|
< 0.001
|
|
GNRI (%)
|
95 [89–101]
|
94 [89–100]
|
0.01
|
|
BUN (mg/dL)
|
63 ± 14
|
59 ± 14
|
< 0.001
|
|
Cr (mg/dL)
|
10.5 ± 2.7
|
10.6 ± 2.6
|
0.2
|
|
Alb (g/dL)
|
3.6 [3.4–3.8]
|
3.6 [3.4–3.8]
|
0.02
|
|
Corrected Ca (mg/dL)
|
9.1 [8.7–9.6]
|
9.2 [8.8–9.6]
|
0.01
|
|
Serum phosphorus (mg/dL)
|
5.4 [4.7–6.2]
|
5.2 [4.5–6.0]
|
< 0.001
|
|
I-PTH (pg/dL)
|
147 [83–213]
|
127 [76–210]
|
< 0.001
|
|
Hb (g/dL)
|
10.8 [10.2–11.4]
|
10.8 [10.2–11.4]
|
0.8
|
|
Ferritin (ng/mL)
|
56 [24–134]
|
64 [24–144]
|
0.08
|
|
TSAT (%)
|
26 [18–40]
|
27 [19–43]
|
0.04
|
|
Kt/V
|
1.4 [1.3–1.6]
|
1.5 [1.3–1.6]
|
< 0.001
|